NuVision® is an expert team of scientific, clinical and insustry professionals dedicated to building innovative ocular biotherapies. Our work is rooted in our values.
NuVision was founded in 2015 based on 15 years of translational research at the University of Nottingham. Research and innovation are still at our core as we continue to develop new technologies. We’re building our portfolio of ocular biotherapies to ensure no patient goes without immediate access to treatment.
Meet the team
Dr. Mark Treherne
Mark joined NuVision in 2018 as Chairman bringing with him over 25 years of industrial R&D experience in the discovery and development of treatments for diseases with unmet need.
Mark began his research career with a PhD in Pharmacology from the University of Cambridge, followed by research with Pfizer and the setting up of life sciences software company, Cambridge Drug Discovery (CDD) as Chief Executive, sold as BioFocus in 2001.
Mark was Chairman of the non-profit ERBI (now One Nucleus) for 3 years, representing biotechnology companies in the East of England, and Chief Executive of the Life Sciences Organisation of UK Trade and Investment until 2016.
Mark has authored over 70 articles in the scientific and trade press.
Chief Executive Officer
Andy joined NuVision with over 35 years’ experience in the European and US medical device industry and has both entrepreneurial and hands-on experience of building the early stages of business with new and disruptive technologies.
Andy’s previous experience includes co-founding and launching Intelligent Ultrasound Limited out of the University of Oxford in 2010, providing first-hand experience of technology transfer and the UK university spin-out environment. Andy was one of the key leaders in taking PercuSurge Inc. from first-in-man trials to their $225m trade sale to Medtronic Inc. He leaves AI-based imaging analytics business Seōn Diagnostics limited to join NuVision. Andy has a keen interest in early-stage development and scaling of healthcare technologies within the UK.
Dr Andrew Hopkinson
Founder and Chief Scientific Officer
Andrew is the founder of NuVision with over 15 years’ experience in translational ophthalmic academic research at the University of Nottingham Ophthalmology department.
Andrew remains an honorary senior academic with the University and together with the multidisciplinary research team at the University of Nottingham, he continues developing innovative technologies to repair and regenerate the ocular surface. This research pioneered the development of Tereo® processing and Omnigen. He continues to research in this area, fuelling the future of innovative biotherapies for NuVision.
Independent Non-Executive Director
Roger joined as Independent Non-Executive Director in 2018. Roger has a track record of driving revenue and profit in the medical device industry.
He enjoyed a 25 year long career at Smith & Nephew – a FTSE 100 medical device business focused on Advanced Wound Management and Advanced Surgical Devices with sales exceeding $4.8 billion and operations in 120 countries. During this time, he was President of the Global Advanced Wound Management business with sales of $1.4 billion, overseeing 4,000 people in 80 countries. Most recently he was Group Managing Director at the Premier Technical Services Group. Roger holds a BA in Accounting and Management Control and is a Chartered Accountant.
Adrian Del Arenal
Operations Manager and Designated Individual
Adrian joined NuVision in 2017 as an Intern Manufacturing Technician and was appointed Operations Manager in 2018 and has since been appointed our HTA designated individual.
He is responsible for overseeing procurement, sales order processing and operations in general. Adrian is a biotechnology engineer from the Monterrey Institute of Technology in Mexico with pilot plant lab experience in recombination protein bioprocessing. He has a MSc from the University of Nottingham in Biopharmaceutics and Business and completed an internship at an SME at BioCity.
Regulatory and Scientific Affairs
Geert joined NuVision® in 2019 as Regulatory Manager. He first started working in tissue banking in 2002 while managing one of two heart valve banks in South Africa.
He was responsible for national supply of quality-controlled cryopreserved human cardiac valves for transplant in South Africa. In 2004, he expanded this focus to include a program for processing of human amniotic membrane-based therapies for ophthalmic use in South Africa before further expanding into umbilical cord blood serum eye drops.
Upon moving to the UK Geert has continued in tissue banking, joining Moorfield Eye Hospital as the Manager and Designated Individual for the Moorfields Lions Eye Bank in 2017.
Geert holds a MSc in Biological Science from the University of South Africa.
Dush joined in 2020 as a Medical Advisor bringing in over 27 years of experience as a Clinician, Researcher, Educator and Executive Director in the NHS.
Dush began his career with a Medical Degree from St George’s Hospital Medical School, University of London and is currently an NHS Consultant in Blood Borne Viruses at Milton Keynes University Hospital and Clinical Lecturer at the University of Buckingham Medical School. He is also a Regional Lead for Infectious Diseases & Microbiology for the National Institute of Healthcare Research (NIHR) and is currently a Principal Investigator for several COVID-19 and HIV related clinical trials. He has over 50 publications and abstracts in his areas of medical expertise.
Medical Science Liaison
Tonicha is responsible for the medical affairs functionality of NuVision. She helps create and disseminate new clinical literature regarding amniotic membrane use.
Tonicha facilities the application of Omnigen in clinical practice, by supporting our customer base, both digitally and face-to-face. She joined NuVision in 2018 after completing her MChem in Medicinal Chemistry at the University of Leeds.
Dr Emily Britchford
Medical Affairs Officer
Emily is experienced in both academic and applied scientific research. She holds a PhD in Tissue Engineering from the University of Nottingham where she was part of the EPSRC doctor training program in regenerative medicine.
Emily was previously a post-doctoral research associate in Academic Ophthalmology at the University of Nottingham where she is focused on the development of Omnigen for acute ocular surface trauma.
Senior Compliance Officer
Shahin has over 20 years experience in Quality and Regulatory Affairs in the Medical Devices and Human Tissue industries.
During his experience, Shahin has been the head of both large and small multi-function teams, locally and globally, to successfully run quality and regulatory departments. Shahin has previously been in roles as the Head of Quality, QA/RA International Manager and the QA/RA Project Manager.